NATCOPHARM · NSE
Not in active coverage. Cited reporting has mentioned Natco Pharma, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Natco Pharma has approved raising up to ₹1,279 crore through a rights issue.
Natco Pharma's board of directors has approved the issuance of equity shares through a rights issue to raise up to ₹1,279.35 crore.
The board of Natco Pharma approved fund raising not exceeding Rs 1,300 crore by way of a rights issue at its meeting held on 09 September 2026.
Natco Pharma acquired a 35.75% stake in South African firm Adcock Ingram in July 2025 for $226 million and raised its stake to 49% with a total investment of approximately $315.4 million.
Natco Pharma invested an additional $14 million in eGenesis Inc, a US-based biotechnology company developing genome-engineered transplantable organs, bringing its total investment to $22 million.
Natco Pharma is investing $14 million in eGenesis Inc through its two subsidiaries, with Natco Pharma (Canada) Inc investing $9.5 million and Natco Pharma South Africa Proprietary Ltd investing $4.5 million via convertible promissory notes.
Natco Pharma is among 15 stocks turning ex-dividend on Thursday with a record date of August 20.
Natco Pharma reported a 44.7% year-on-year decline in operating revenue to Rs 735 crore for the first quarter ended June 2026, with Ebitda crashing 61% to Rs 236 crore.
Nearly 100 companies including Bandhan Bank, HUDCO, Manappuram Finance, NBCC, Mahanagar Gas, Mazagon Dock Shipbuilders, Natco Pharma, and LIC Housing Finance have fixed record dates for dividends, bonus issues, and stock splits between August 17 and August 21, 2026.
This page lists where cited reporting has mentioned Natco Pharma. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.